#glaxosmithkline Tech News.
1 story in the last 7 days
The latest glaxosmithkline news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks glaxosmithkline across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
FinanceSeeking Alpha1 day ago
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase InhibitorsGlaxoSmithKline is acquiring Nuvalent for $10.6 billion ($124 per share), capping upside and earning a 'Hold' rating. Nuvalent's selective TKIs neladalkib and zidesamtinib posted positive pivotal trial results in ALK-positive and ROS1-positive NSCLC, with NDAs submitted and 2026 PDUFA dates set.
Summaries by ByteBrief